PRTN3 and myelodysplastic syndrome: The screening analysis for anti-MPO, anti-PR3 and anti-CCP3 autoantibodies showed positive results only in the MDS cohort; results from 1:80 diluted samples showed one anti-CCP3 positive patients (1/50 pts; 2%), and this positivity was also confirmed at ≥ 1:160 clinically relevant cut-off (1/19; 5.2%), Supplementary Fig. 5.